MedTrace Logo

A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects

NCT05023811 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-01-10

No results posted yet for this study

Summary

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of \[14C\]RIST4721 Following a Single Oral Dose to Healthy Male Subjects

Conditions

  • Healthy
  • ADME

Interventions

DRUG

[14C]RIST4271

\[14C\]RIST4271 oral solution

Sponsors & Collaborators

  • Aristea Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2021-09-15
Completion
2021-09-15
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023811 on ClinicalTrials.gov